While some EGFR inhibitors like erlotinib and nimotuzumab have shown efficacy, others have failed to yield significant results in clinical trials for pancreatic ductal adenocarcinoma, suggesting potential resistance mechanisms within pancreatic ductal adenocarcinoma to EGFR inhibitors (Moll et al. 2018; Jacobsen et al. 2015). This evidence concerns the gene EGFR and pancreatic ductal adenocarcinoma.